Material Specification
≥99.8% (USP Reagent Grade)
Medical and laboratory grade structural material
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: acetic-acid-water-0-6
Validated Laboratory Standard
Aseptic Reconstitution Laboratory StandardsSingle Peptide
0.6% Acetic Acid Water
Revision 1 · Aqueous solution (0.6% v/v glacial acetic acid in sterile endotoxin-free water)
Sterile 0.6% Acetic Acid Diluent for IGF-1 LR3 & Hydrophobic Peptides. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
0.6% Acetic Acid Water
Sterile 0.6% Acetic Acid Diluent for IGF-1 LR3 & Hydrophobic Peptides. Formulated for in-vitro research and laboratory analytical validation.
≥99.8% (USP Reagent Grade)Laboratory Supplies
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~2 to 6 HoursCirculating plasma half-life or active receptor persistence.
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical Specification0.6% Acetic Acid Reconstitution Solvent is an essential laboratory reagent specially formulated for dissolving and stabilizing peptides prone to isoelectric aggregation at neutral pH (notably IGF-1 LR3, IGF-1 DES, and Long-R3). Buffered to an acidic pH of 2.8–3.2 with reagent-grade glacial acetic acid in endotoxin-free water, it maintains peptide monomer stability and biological potency during long-term refrigeration.
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
Acidic Reconstitution Matrix: Prevents irreversible self-aggregation and precipitation of IGF-1 LR3.
✓
Extended Liquid Stability: Maintains biological potency of reconstituted IGF-1 LR3 for up to 12 months at 2°C–8°C.
Physicochemical Specifications & Analytical Verification
≥99.8% (USP Reagent Grade)Primary Sequence / Chemical Formula
CH3COOH (0.6% w/v in H2O)
Sterility Standard
Aseptic Laboratory Standard
Certified sterile and non-pyrogenic for research handling
Storage Standard
Store at 15°C–25°C room temperature.
Store in clean, dry laboratory environment
Classification
Laboratory Hardware & Consumables
Standard laboratory reconstitution and storage equipment
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (60 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake60 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent10.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution6.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 60.0 mcg (0.01 mL)| Standard Compound Mass | 60 mg active per vial |
| Recommended Diluent | 0.6% Glacial Acetic Acid in Sterile Deionized Water |
| Diluent Volume Added | 10.0 mL |
| Resulting Concentration | 6.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 60.0 mcg (0.01 mL)) |
| Handling Rule | Aseptic technique mandatory. Store at 15°C–25°C. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— 0.6% Acetic Acid Water
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger
1. Compound Mass60 mg
mg
Vials:
2. Diluent Volume10.0 mL
mL
Quick:
3. Target Assay Dose16.7 Units
Dissolution Vial
60mg / 10mL
Syringe: 100 U (1.0 mL Workhorse)
16.7 Units (0.167 mL)
0 U100 U
💡Micro-Dose Accuracy: Low draw (16.7 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.
Selected Dose
1 mg
1000 µg active mass
Injection Volume
0.167 mL
167 µL draw
U-100 Syringe Mark
16.7 Units
Barrel Graduation
Single Vial Yield
~60.0 Doses
60 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: 0.6% Acetic Acid Water•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (60mg / 10.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (At Reconstitution) | 1 mg | 16.7 Units(0.17 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 60mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 12.0 mg
Active Vials (60mg):1 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 24.0 mg
Active Vials (60mg):1 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 16.7 Units (0.17 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 0.5 mL (50 IU) | 0.50 mL | 50 Units 0.5 mL (3,000 mcg) |
| 1.0 mL (100 IU) | 1.00 mL | 100 Units 1.0 mL (6,000 mcg) |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
×
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle:
Active Compound Mass60 mgSingle Lyophilized Vial
Diluent Volume Added10.0 mLBacteriostatic Water USP
Resulting Concentration6.00 mg/mLHomogenized Solution
Vial Yield~60.0 DosesPer Single Reconstituted Vial
Target Analytical Dose1 mg1000 µg active mass
Volumetric Draw0.167 mL (167 µL)Calibrated Liquid Draw
U-100 Syringe Graduation16.7 UnitsPlunger Barrel Mark
Standard 1 mL Luer Lock or U-100 LDS Syringe
Target: 100.0 IU = 1.0 mL (6,000 mcg solute)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 0.5 mL (50 IU) | 0.5 mL (500 µL) | 50 Units | 0.5 mL (3,000 mcg) |
| 1.0 mL (100 IU) | 1 mL (1000 µL) | 100 Units | 1.0 mL (6,000 mcg) |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
50 U-100 Units (0.5 mL)
Mass @ 6.0 mg/mL:3 mg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:1 mL Barrel Standard
✓ Exact Tick Mark Alignment (50 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 50.0% of barrel
Tick Increment
2 Unit (20 µL)
Volumetric step
Low-Dead-Space (LDS)
<2.1 µL (0.42%)
Integrated needle waste
Measurement Error
±4.5%
ISO 8537 tolerance
Needle Configuration
29G (0.33mm)
1/2" (12.7mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (0.6% Acetic Acid Water)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 2.1 µL
Wastage per Titration:0.42% of dose
84-Day Cumulative Loss:1.058 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:9.9% of dose
84-Day Cumulative Loss:27.72 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 50 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units) | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✕ Exceeded by 20 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 50 units |
| 1 mL (100 Units)BEST FIT | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 50 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for 0.6% Acetic Acid Water.
Active Compound
84.00 mg
Across 12 weeks (84 doses)
Vials Required
2 × 60mg
Includes 8% dead-space buffer
Bacteriostatic Water
2 × 10 mL Bottles
20.0 mL total diluent
Sterile Syringes
90 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
180 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 2 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(53mg rem) | 7.0 mg / 84.0 mg |
| Week 2 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(46mg rem) | 14.0 mg / 84.0 mg |
| Week 3 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(39mg rem) | 21.0 mg / 84.0 mg |
| Week 4 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(32mg rem) | 28.0 mg / 84.0 mg |
| Week 5 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(25mg rem) | 35.0 mg / 84.0 mg |
| Week 6 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(18mg rem) | 42.0 mg / 84.0 mg |
| Week 7 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(11mg rem) | 49.0 mg / 84.0 mg |
| Week 8 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #1(4mg rem) | 56.0 mg / 84.0 mg |
| Week 9 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #2(53mg rem) | 63.0 mg / 84.0 mg |
| Week 10 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #2(46mg rem) | 70.0 mg / 84.0 mg |
| Week 11 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #2(39mg rem) | 77.0 mg / 84.0 mg |
| Week 12 | Solvent Dispensing (At Reconstitution) | 1.0 mg(7x/wk) | 16.7 Units(0.17 mL) | Vial #2(32mg rem) | 84.0 mg / 84.0 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: Solvent Shelf Life: 24 Months · Washout: N/A
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| At ReconstitutionStarting Baseline | 1 mg | Once | Solvent Dispensing: Acidic pH stabilization (pH 2.8–3.2) (Maintains positive molecular charge) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓Acidic Reconstitution Matrix: Prevents irreversible self-aggregation and precipitation of IGF-1 LR3.
✓Extended Liquid Stability: Maintains biological potency of reconstituted IGF-1 LR3 for up to 12 months at 2°C–8°C.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes!Localized Stinging: Mild transient injection sting if administered without prior buffer dilution.
Preparation and Handling SOP
Standard laboratory handling: undefined. undefined: undefined undefined. undefined: undefined undefined. undefined: undefined undefined. undefined: undefined
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
Store at 15°C–25°C room temperature.
Reconstituted Solution
Store at room temperature or 2°C–8°C.
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for 0.6% Acetic Acid Water
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at Store at 15°C–25°C room temperature.. Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (1 References)
Peer-Reviewed IndexVerified scientific reference.
Frequently Asked Questions
How should 0.6% Acetic Acid Water be reconstituted?
Ready to use sterile solution. Draw required volume as reconstitution solvent.
What is the estimated laboratory half-life of 0.6% Acetic Acid Water?
0.6% Acetic Acid Water displays an estimated half-life of N/A. Typical study protocols run for Solvent Shelf Life: 24 Months followed by a washout period of N/A.
Technical Overview & Material Specifications
0.6% Acetic Acid Reconstitution Solvent is an essential laboratory reagent specially formulated for dissolving and stabilizing peptides prone to isoelectric aggregation at neutral pH (notably IGF-1 LR3, IGF-1 DES, and Long-R3). Buffered to an acidic pH of 2.8–3.2 with reagent-grade glacial acetic acid in endotoxin-free water, it maintains peptide monomer stability and biological potency during long-term refrigeration.
Standard Operating Procedure (SOP)
Step undefined: undefined
undefined
Step undefined: undefined
undefined
Step undefined: undefined
undefined
Step undefined: undefined
undefined
Key Features & Quality Standards
• undefined: undefined
• undefined: undefined
• undefined: undefined
• undefined: undefined
Available in Catalog
0.6% Acetic Acid Water (10 mL Laboratory Reagent)
High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).
Strictly for in vitro and academic laboratory research purposes only. Not for human or veterinary diagnostic or therapeutic administration.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
0.6% Acetic Acid Water
Standard Lyophilized Monograph
Doc ID: PSL-SOP-ACETICACID-REV1Rev: 1Category: Laboratory SuppliesDate: September 29, 2026
QR CODE
Verify Lot COApepstacklabs.com/ph/research-protocols/acetic-acid-water-0-6Pharmacological Profile & Monograph
Sterile 0.6% Acetic Acid Diluent for IGF-1 LR3 & Hydrophobic Peptides. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:0.6% Acetic Acid Water
CAS Registry Number:64-19-7
PubChem CID:176
Molecular Weight:60.05 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:CH3COOH (0.6% w/v in H2O)
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · 0.6% ACETIC ACID WATERDOC ID: PSL-SOP-ACETICACID-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 60 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 10.0 mL | 6.00 mg/mL | 1 Unit = 60.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 16.7 Units (0.167 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 16.7 Units (0.167 mL)30 U (0.3 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 10.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · 0.6% ACETIC ACID WATERDOC ID: PSL-SOP-ACETICACID-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 1.0 mg | 16.7 Units (0.167 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 1.5 mg | 25.0 Units (0.250 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 1.0 mg | 16.7 Units (0.167 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 60mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-ACETICACID-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3